摘要
目的:分析采用仑伐替尼联合肝动脉化疗栓塞术(TACE)对中晚期肝癌患者的影响。方法:选取2020年3月-2022年3月在漳州市医院治疗的80例中晚期肝癌患者,随机将其分为观察组和对照组,各40例,对照组采用TACE治疗,观察组采用仑伐替尼联合TACE进行治疗,比较两组治疗效果、生活质量、肿瘤标志物水平及不良反应发生情况。结果:两组治疗效果比较,观察组客观缓解率(ORR)和疾病控制情况(DCR)明显高于对照组(P<0.05);治疗前,两组甲胎蛋白(AFP)、癌胚抗原(CEA)、成纤维细胞生长因子(FGF)和血管内皮细胞生长因子(VEGF)水平比较差异无统计学意义(P>0.05),治疗后1个月,两组肿瘤标志物水平较治疗前更低(P<0.05),且观察组肿瘤标志物水平明显低于对照组(P<0.05);治疗前,两组生活质量各维度评分比较差异无统计学意义(P>0.05),两组治疗后1个月生活质量明显高于治疗前(P<0.05),且观察组生活质量评分明显较对照组高(P<0.05),观察组不良反应发生率略高于对照组,差异无统计学意义(P>0.05)。结论:应用仑伐替尼联合TACE治疗中晚期肝癌患者,能够降低患者肿瘤标志物水平,缓解患者病情的进展,改善患者的生活质量,且疗效安全可靠。
Objective:To analyze the effect of Lenvatinib combined with transcatheter arterial chemoembolization(TACE)on patients with advanced liver cancer.Method:A total of 80 patients with advanced liver cancer who were treated in Zhangzhou Municipal Hospital from March 2020 to March 2022 were selected and randomly divided into observation group and control group,40 cases in each group.The control group was treated with TACE,and the observation group was treated with Lenvatinib combined with TACE.The treatment effect,quality of life,tumor markers levels and adverse reactions of the two groups were compared.Result:The objective remission rate(ORR)and disease control rate(DCR)in the observation group were significantly higher than those in the control group(P<0.05).Before treatment,there were no significant differences in the levels of alpha fetoprotein(AFP),carcinoembryonic antigen(CEA),fibroblast growth factor(FGF)and vascular endothelial growth factor(VEGF)between the two groups(P>0.05).One month after treatment,the levels of tumor markers in the two groups were lower than those before treatment(P<0.05),and the levels of tumor markers in the observation group were significantly lower than those in the control group(P<0.05).Before treatment,there were no significant differences in the scores of all dimensions of quality of life between the two groups(P>0.05);the scores of quality of life of the two groups after 1 month of treatment were significantly higher than those before treatment(P<0.05),and the quality of life scores of the observation group were significantly higher than those of the control group(P<0.05).The incidence of adverse reactions in observation group was slightly higher than that in control group,and the difference was not statistically significant(P>0.05).Conclusion:The application of Lenvatinib combined with TACE in the treatment of patients with advanced liver cancer can reduce the level of tumor markers,alleviate the progress of patients’condition,improve the quality of life of patients,and the cura
作者
张凤琦
翁凌凌
ZHANG Fengqi;WENG Lingling(Zhangzhou Municipal Hospital,Zhangzhou 363000,China;不详)
出处
《中外医学研究》
2022年第31期33-37,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
